Management Team

John F. Dee, President and Chief Executive Office

John joined Link in May, 2009. Previously, John served as President and Chief Executive Officer of Hypnion, Inc. from its founding in 2000 until its sale to Eli Lilly in 2007 for $325 million. Under his leadership, Hypnion raised approximately $70 million in venture capital, built a world-class scientific team and technology platform, advanced 5 drugs into clinical trials, and positioned itself as the leader in sleep disorder research and development. Prior to Hypnion, John spent a significant portion of his professional career with McKinsey & Co., Inc., where he conducted performance-improvement and strategic growth initiatives for several major energy and pharmaceutical companies. John has also served on several Boards of Directors, including Executive Chairman of Neurophage, Inc., Executive Chairman of Bioprocessors, Inc., and as a director of Verenium, Inc. In non-profit pursuits, John led a group of Bay Area economists and business leaders in a diagnostic and public policy review of the San Francisco Bay Area’s economic performance. John holds an M.S. in Engineering from Stanford University and an M.B.A. from Harvard University.

Peter T. Lansbury, Jr., PhD, Chief Scientific Officer

A leader in the scientific understanding of protein misfolding and aggregation in neurodegeneration Peter founded Link in March 2005. In addition to serving as Link's Chief Scientific Officer, Peter also retains his position as a part-time professor of neurology at Harvard Medical School, and Director of the Morris K. Udall Research Center of Excellence in Parkinson's Disease at Brigham and Women's Hospital.

Mark E. Duggan, PhD, Vice President of Chemistry

Mark joined Link in October 2008, with over 20 years of experience in the pharmaceutical and biotechnology industry. Prior to Link, Mark was Head of the Medicinal Chemistry Department at Amgen in Cambridge, MA. Previously he spent 18 years at Merck & Co., where he rose to the level of Senior Director in the Department of Medicinal Chemistry. At Merck, Mark successfully led programs in the areas of bone biology, endocrinology and neuroscience, was a co-inventor of Aggrastat^®, and served as co-chair of an early development team.

Berkley Lynch, PhD, Vice President of Discovery Research

Berkley joined Link in October 2007, as Senior Director of Discovery Research. He has over 15 years of experience in the biotechnology industry. Prior to Link, Berkley worked for 7 years at UCB Pharma, where he lead a team focused on initiating drug development aimed at novel targets for the treatment of Epilepsy. At UCB, Berkley also identified the synaptic vesicle protein SV2A as the brain binding site of the antiepileptic drug levetiracetam. Berkley started his career in the early 1990s at ARIAD Pharmaceuticals, where he started and managed a high-throughput screening group.

Michael E. Solomon, PhD, Chief Business and Technology Officer

Mike joined Link in June, 2009. Prior to Link, Mike was a founding member and interim VP of Molecular Discovery of Epizyme, Inc, a biotechnology company focused on developing epigenetic treatments for disease. During this time, he also provided drug discovery and strategic business advice to several biotechnology companies and leading venture capital firms. Prior to Epizyme, Mike was VP of Research and Alliance Management at Hypnion Inc. He had broad responsibilities including drug discovery, preclinical development, as well as business development and in-licensing efforts. In 2002, Mike became a Senior Associate in the Biotechnology Research Group at Banc of America Securities where he assisted in the coverage of over 15 small to large cap biotechnology companies. Mike began his career at Millennium Pharmaceuticals where he rose to become Project Leader of several Metabolic Disease Projects. In 2001, he became Manager of Business Development, where he contributed to value-creation strategies for non-core assets. Mike received his BS from the University of Massachusetts, Amherst, his PhD in Organic Chemistry at the University of Wisconsin, and conducted post-doctorate research at Scripps Research Institute.

Scott L. Young, Chief Operating Officer

Scott joined Link in December 2006 as COO. Prior to joining Link, Scott served as Chief Operating Officer for OXiGENE, Inc., a publicly-traded oncology therapeutics development company, and previously Scott held positions in clinical/regulatory affairs, GMP manufacturing operations and process development at Genzyme Corporation and RepliGen Corporation. In his early career he was a laboratory research and development scientist at Genetics Institute (now part of Wyeth) and the University of Massachusetts.

Michael E. Fitzgerald, Senior Vice President, Finance and Administration Chief Financial Officer

Michael joined Link in July, 2009. Prior to Link Michael served as Hypnion Inc.’s Chief Financial Officer and Vice President of Finance and Administration since the company's founding in July 2000. During his tenure, Hypnion has raised approximately $70 million in venture capital. As Senior Vice President of Finance and Administration, and Chief Financial Officer of CytoMed, Inc. from 1992 to 1999, Michael negotiated, developed and executed financial terms for numerous collaborations. Prior to his work at CytoMed, he served as Corporate Controller and Chief Accounting Officer of BioTechnica International, Inc., an agricultural biotechnology firm. From January 1975 to August 1986, Michael held various accounting positions with Amicon Corporation, the life sciences group of W.R. Grace Inc. Michael graduated from Bentley College with a B.S. in Economics and Finance and an M.B.A. in Finance.


Overview Management Team Scientific Advisory Board Board of Directors	Management Team John F. Dee, President and Chief Executive Office John joined Link in May, 2009. Previously, John served as President and Chief Executive Officer of Hypnion, Inc. from its founding in 2000 until its sale to Eli Lilly in 2007 for $325 million. Under his leadership, Hypnion raised approximately $70 million in venture capital, built a world-class scientific team and technology platform, advanced 5 drugs into clinical trials, and positioned itself as the leader in sleep disorder research and development. Prior to Hypnion, John spent a significant portion of his professional career with McKinsey & Co., Inc., where he conducted performance-improvement and strategic growth initiatives for several major energy and pharmaceutical companies. John has also served on several Boards of Directors, including Executive Chairman of Neurophage, Inc., Executive Chairman of Bioprocessors, Inc., and as a director of Verenium, Inc. In non-profit pursuits, John led a group of Bay Area economists and business leaders in a diagnostic and public policy review of the San Francisco Bay Area’s economic performance. John holds an M.S. in Engineering from Stanford University and an M.B.A. from Harvard University. Peter T. Lansbury, Jr., PhD, Chief Scientific Officer A leader in the scientific understanding of protein misfolding and aggregation in neurodegeneration Peter founded Link in March 2005. In addition to serving as Link's Chief Scientific Officer, Peter also retains his position as a part-time professor of neurology at Harvard Medical School, and Director of the Morris K. Udall Research Center of Excellence in Parkinson's Disease at Brigham and Women's Hospital. Mark E. Duggan, PhD, Vice President of Chemistry Mark joined Link in October 2008, with over 20 years of experience in the pharmaceutical and biotechnology industry. Prior to Link, Mark was Head of the Medicinal Chemistry Department at Amgen in Cambridge, MA. Previously he spent 18 years at Merck & Co., where he rose to the level of Senior Director in the Department of Medicinal Chemistry. At Merck, Mark successfully led programs in the areas of bone biology, endocrinology and neuroscience, was a co-inventor of Aggrastat^®, and served as co-chair of an early development team. Berkley Lynch, PhD, Vice President of Discovery Research Berkley joined Link in October 2007, as Senior Director of Discovery Research. He has over 15 years of experience in the biotechnology industry. Prior to Link, Berkley worked for 7 years at UCB Pharma, where he lead a team focused on initiating drug development aimed at novel targets for the treatment of Epilepsy. At UCB, Berkley also identified the synaptic vesicle protein SV2A as the brain binding site of the antiepileptic drug levetiracetam. Berkley started his career in the early 1990s at ARIAD Pharmaceuticals, where he started and managed a high-throughput screening group. Michael E. Solomon, PhD, Chief Business and Technology Officer Mike joined Link in June, 2009. Prior to Link, Mike was a founding member and interim VP of Molecular Discovery of Epizyme, Inc, a biotechnology company focused on developing epigenetic treatments for disease. During this time, he also provided drug discovery and strategic business advice to several biotechnology companies and leading venture capital firms. Prior to Epizyme, Mike was VP of Research and Alliance Management at Hypnion Inc. He had broad responsibilities including drug discovery, preclinical development, as well as business development and in-licensing efforts. In 2002, Mike became a Senior Associate in the Biotechnology Research Group at Banc of America Securities where he assisted in the coverage of over 15 small to large cap biotechnology companies. Mike began his career at Millennium Pharmaceuticals where he rose to become Project Leader of several Metabolic Disease Projects. In 2001, he became Manager of Business Development, where he contributed to value-creation strategies for non-core assets. Mike received his BS from the University of Massachusetts, Amherst, his PhD in Organic Chemistry at the University of Wisconsin, and conducted post-doctorate research at Scripps Research Institute. Scott L. Young, Chief Operating Officer Scott joined Link in December 2006 as COO. Prior to joining Link, Scott served as Chief Operating Officer for OXiGENE, Inc., a publicly-traded oncology therapeutics development company, and previously Scott held positions in clinical/regulatory affairs, GMP manufacturing operations and process development at Genzyme Corporation and RepliGen Corporation. In his early career he was a laboratory research and development scientist at Genetics Institute (now part of Wyeth) and the University of Massachusetts. Michael E. Fitzgerald, Senior Vice President, Finance and Administration Chief Financial Officer Michael joined Link in July, 2009. Prior to Link Michael served as Hypnion Inc.’s Chief Financial Officer and Vice President of Finance and Administration since the company's founding in July 2000. During his tenure, Hypnion has raised approximately $70 million in venture capital. As Senior Vice President of Finance and Administration, and Chief Financial Officer of CytoMed, Inc. from 1992 to 1999, Michael negotiated, developed and executed financial terms for numerous collaborations. Prior to his work at CytoMed, he served as Corporate Controller and Chief Accounting Officer of BioTechnica International, Inc., an agricultural biotechnology firm. From January 1975 to August 1986, Michael held various accounting positions with Amicon Corporation, the life sciences group of W.R. Grace Inc. Michael graduated from Bentley College with a B.S. in Economics and Finance and an M.B.A. in Finance.